期刊
ANNALS OF ONCOLOGY
卷 32, 期 2, 页码 183-196出版社
ELSEVIER
DOI: 10.1016/j.annonc.2020.11.013
关键词
Pancreatic cancer; preoperative; neoadjuvant; precision medicine; prognostic biomarkers; predictive biomarkers
类别
资金
- Cancer Research UK [C29717/A17263, C29717/A18484, C596/A18076, C596/A20921, A23526]
- Wellcome Trust [103721/Z/14/Z]
This review emphasizes the importance of personalized therapeutic approaches based on genomic factors in the preoperative setting for pancreatic cancer to reduce mortality rates.
This review summarises the recent evidence on preoperative therapeutic strategies in pancreatic cancer and discusses the rationale for an imminent need for a personalised therapeutic approach in non-metastatic disease. The molecular diversity of pancreatic cancer and its influence on prognosis and treatment response, combined with the failure of 'allcomer' treatments to significantly impact on patient outcomes, requires a paradigm shift towards a genomic-driven approach. This is particularly important in the preoperative, potentially curable setting, where a personalised treatment allocation has the substantial potential to reduce pancreatic cancer mortality.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据